You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameVEGF Receptor 2 protein (Fc Chimera)See all VEGF Receptor 2 proteins and peptides ...
  • Protein descriptionRecombinant fragment: human soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2) was fused with the Fc part of human IgG1 and expressed in Insect cells. The recombinant sVEGFR2/Fc is a disulfide-linked homodimeric protein, M.Wt of the monomer is 160 kDa and it contains all 7 extracellular domains of VEGFR2.
  • Expression hostInsect cells

    • Properties

  • Purity> 90 % by SDS-PAGE
  • Purification notesab54259 purity was visualised by Silver stain. Endotoxin level: < 0.1 ng per ug of sVEGFR2
  • FormLyophilised:sVEGFR 2/Fc should be reconstituted in PBS or medium to a concentration not lower than 50 µg/ml.
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: PBS, pH 7.4
  • Concentration information loading...
  • Research Areas

    • Applications

    Our Abpromise guarantee covers the use of ab54259 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Notes
    SDS-PAGE
    Functional Studies
  • Application notesSDS-PAGE: Use at an assay dependent dilution.
    Biological Activity: The activity of sVEGFR2/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.

    • Protein info

    • Alternative names
        CD309CD309 antigenFetal liver kinase 1
        FLK-1FLK1KDRKinase insert domain receptorKinase insert domain receptor (a type III receptor tyrosine kinase)KRD1Ly73Protein tyrosine kinase receptor FLK1Protein-tyrosine kinase receptor flk-1Tyrosine kinase growth factor receptorVascular endothelial growth factor receptor 2VEGFRVEGFR 2VEGFR-2VEGFR2VGFR2_HUMAN
      see all
  • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localizationMembrane.

    • Target information above from: UniProt accession P35968 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt

    References for VEGF Receptor 2 protein (Fc Chimera) (ab54259)

    This product has been referenced in:
    • Kaczmarek MM  et al. Assessment of VEGF-receptor system expression in the porcine endometrial stromal cells in response to insulin-like growth factor-I, relaxin, oxytocin and prostaglandin E2. Mol Cell Endocrinol 291:33-41 (2008). Read more (PubMed: 18562087) »

    See 1 Publication for this product

    Publishing research using ab54259 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit an Abreview for ab54259 Submit a Question for ab54259

    There are currently no Abreviews or Questions for ab54259.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"